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Neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) is considered as one of the major manifestations of the
disease. Epilepsy has been documented in about 10% of patients with systemic lupus erythematosus (SLE). It is well known that
vascular damage in SLE occurs because of multiple mechanisms including hypercoagulation. It has been recently reported that
in SLE patients raised levels of homocysteine are associated with arterial thrombosis. Hyperhomocysteinaemia is a condition
due to both genetic and non-genetic factors. The most common genetic defect in homocysteine metabolism is a decreased
activity of a common 5,10-methylenetetrahydrofolate reductase (MTHFR) variant (677C→T, a thermolabile form).
In this paper we describe the epileptic manifestations in six out of 55 SLE patients. Seizures were the SLE onset symptom for
three patients, appeared during the active disease in two cases, and occurred during a period of clinical remission in one patient.
In all cases we documented the association of epilepsy with the MTHFR mutation: the homozygosity form was present in one
case (16.7%), and heterozygosity in five cases (83.3%). Nevertheless, levels of homocysteine in plasma were in the normal
range. Moreover, we found a decrease in the level of S protein values in one case, a high titre positivity of anticardiolipin
antibodies (aCL) (IgG and IgM) in three patients and low titre positivity (IgG) in one patient, and lupus anticoagulant (LAC)
positivity in four cases.
In conclusion, we believe that the abnormalities of coagulation present in our patients could be related to epileptogenesis or
to an alteration of the seizure threshold.
c© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved
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INTRODUCTION
Systemic lupus erythematosus (SLE) is characterized
by the production of a wide range of autoanti-
bodies that play a role in the generation of organ
damage. Criteria for neuropsychiatric involvement
in SLE (NPSLE) have been recently defined1.
NPSLE has been emphasized as one of the major
manifestations, since the first descriptions of the
disease, and it is among the leading causes of SLE
morbidity and mortality2–4. The reported prevalence
of NPSLE has been as high as 75% but a prevalence of
approximately 20% appears to be more representative.
Epilepsy has been documented in about 10% of
patients with SLE5, 6.
It is well known that vascular damage in SLE occurs
through multiple mechanisms, including immune
complex deposition and vasculitis, hypertension, hy-
perlipidaemia and hypercoagulation. In 1998, Fijnheer
et al.7, in a retrospective cohort study on 175 SLE
patients, reported that raised levels of homocys-
teine (Hcy) are associated with arterial thrombosis.
Hyperhomocysteinaemia is a condition due to both
genetic and non-genetic factors. A common 5,10-
methylene-tetrahydrofolate reductase (MTHFR) vari-
ant (677C→T, a thermolabile form) may induce
elevated homocysteine plasma concentrations. In
SLE patients the distribution of MTHFR genotypes
is 50% for the homozygous wild type, 42% for the
heterozygous, and 8% for the homozygous mutant7.
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Table 1: Coagulation studies in our SLE patients with epilepsy.
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
LAC Neg Pos Pos Neg Pos Pos
aCL IgG IgG/IgM IgG/IgM Neg Neg IgG/IgM
Leiden factor V Neg Neg Neg Neg Neg Neg
Prothrombin mutation Neg Neg Neg Neg Neg Neg
C Protein (n.v. 60–140%) 93 120 130 117 85 70
S Protein (n.v. 65–140%) 98 55a 76 121 77 65
AT III (n.v. 80–120%) 94 98 116 119 101 91
INR (n.v. 0.8–1.2) 1.07 1.2 1.2 1.1 1.05 1.05
APTT (n.v. 28–40 s) 40 71.2a 120 51.5 40 56.8a
Fibrinogen (n.v. 150–400 mg dl−1) 457a 388 353 313 380 332
MTHFR mutation genotypeb +/− +/+ +/− +/− +/− +/−
Homocysteine (n.v. 5–15 mM L−1) 10.5 11.2 10.2 9.8 11.6 11
Age (years) 45 28 49 17 49 41
Onset of SLE (age) 12 18 13 1 28 14
Duration of SLE (years) 33 10 36 16 21 27
Duration of epilepsy (years) 31 8 2 15 13 21
Seizurec A A B A B B
Pos = positive; Neg = negative; aabnormal results; bMTHFR mutation genotype: +/+ = homozygous; +/− = heterozygous; cseizure:
A = SLE onset symptom; B = occurred during the course of SLE.
This mutation has been recently reported also in
epileptic non-SLE patients with a frequency ranging
from 23% for homozygosity and 52% for heterozy-
gosity8.
We are carrying out a study on the thrombophilic
factors in SLE patients with neuropsychiatric manifes-
tations. In a cohort of 55 patients, who fulfilled the
American College of Rheumatology (ACR) criteria
for SLE classification, six had seizures (10.9%). In
the present paper we intend to report the peculiar
results obtained by a coagulation screening in our
SLE patients suffering from epilepsy. In fact, the
distribution of MTHFR mutation was not consistent
with the above mentioned data in the literature, since
it was present in all epileptic patients of our cohort.
Case 1
A 43-year-old woman described a three year history
of weakness, arthralgia, Raynaud’s phenomenon, sicca
syndrome, swollen hands and feet, malar butterfly
erythema and alopecia. Since the age of 12 she has
been complaining of complex partial seizures with
secondary generalization and frontal lobe epilepsy was
diagnosed. EEG revealed fronto-temporal spikes in the
right lobe and treatment with phenytoin was started.
Immunological studies revealed positive of antinu-
clear antibodies (ANA) and anti double stranded-DNA
(ds-DNA). Notwithstanding that ACR criteria were
satisfied, drug related SLE could not be excluded.
Phenytoin therapy was stopped, but clinical conditions
and laboratory findings did not improve. Anticonvul-
sant treatment was replaced with phenobarbitone and
immunosuppressive therapy was started.
A coagulation study revealed positivity for anti-
cardiolipin IgG antibodies (aCL) and heterozygosity
for 677C→T MTHFR mutation (Table 1).
Case 2
A 26-year-old woman presented with menorrhagia,
fever, dyspnoea and chest constriction, weakness and
diffuse arthralgia. From the age of 18 partial seizures,
with secondary generalization, repeatedly occurred.
Visual evoked potentials (VEPs) showed bilateral
abnormalities. EEG revealed abnormal, repetitive,
rhythmic activity in the right occipital area, consis-
tent with epilepsy; in addition, magnetic resonance
imaging (MRI) of the brain showed cortical and
subcortical atrophy without focal lesions. On the basis
of the clinical features and laboratory data, the patient
fulfilled the ACR criteria for SLE classification.
Corticosteroid therapy was started.
Carbamazepine treatment was suspended because of
an increasing titre of ANA, and valproic acid treatment
was started. A coagulation study showed a decrease of
S protein levels, lupus anticoagulant (LAC) and aCL
positivity (IgG/IgM), and homozygosity for 677C→T
MTHFR mutation (Table 1).
Case 3
A 49-year-old woman had a 36-year history of SLE.
During the course of her disease she developed three
episodes of venous thrombosis and a spontaneous
abortion at the 15th week of gestation. LAC posi-
tivity and presence of anticardiolipin IgG and IgM
252 A. Afeltra et al.
antibodies were found. A diagnosis of secondary
antiphospholipid syndrome was made.
When she was 47-year-old she developed temporal
lobe epilepsy. The EEG showed epileptic activity on
the right temporal lobe. She started treatment with
valproic acid. Brain MRI and VEPs were performed,
but they were unremarkable.
A further coagulation study confirmed LAC and
aCL IgG/IgM positivity and revealed heterozygosity
for 677C→T MTHFR mutation (Table 1).
Case 4
A 17-year-old man, since the age of 2, complained
of complex partial seizures with secondary gener-
alization. EEG revealed frontal spikes in the right
lobe, and frontal seizure semeiology was found.
Treatment with phenobarbitone was started. From
the age of 4 the patient fulfilled the clinical and
laboratory ACR criteria for SLE diagnosis (erythema,
arthralgias, lymphopaenia, anaemia, ANA and anti
ds-DNA positivity). Immunosuppressive treatment
was started and notwithstanding the anticonvulsant
therapy, generalized seizures repeatedly occurred.
Thrombophilic screening showed heterozygosity for
677C→T MTHFR mutation (Table 1).
Case 5
A 39-year-old woman had a 23-year history of SLE. At
the age of 20 she presented with pleuritis; three months
later she had a reversible ischaemic attack. When
she was 26-year-old she suffered from generalized
seizures. The EEG showed fronto-temporal activity
in the left lobe. Brain MRI showed subcortical
focal lesions in the left frontal lobe. Treatment with
phenobarbitone was started.
A coagulation study revealed LAC positivity
and heterozygosity for 677C→T MTHFR mutation
(Table 1).
Case 6
A 49-year-old woman presented SLE from the age
of 26. She had a history of a spontaneous abortion at
the 5th month of gestation. When she was 28-year-old,
after a premature birth, she developed complex partial
seizures. EEG showed frontal spikes in the right lobe,
and a frontal seizure semeiology was found. She
was treated with carbamazepine and phenobarbitone.
Moreover, on the basis of LAC and aCL IgG/IgM
positivity, a diagnosis of secondary antiphospholipid
syndrome was made. When she was 34-year-old
she presented with a right hemiparesis. CT scan
and MRI documented a condition of subarachnoid
haemorrhage. At the age of 47 she developed a
transverse myelitis. The coagulation study showed
LAC and aCL IgG/IgM positivity, and heterozygosity
for 677C→T MTHFR mutation (Table 1).
DISCUSSION
The enzyme activity of 5,10-methylenetetrahydro-
folate reductase (MTHFR) catalyzes the reduction
of 5,10-methylenetetrahydrofolate to 5-methyltetra-
hydrofolate. In humans, 5-methyltetrahydrofolate,
a major circulating form of folate, is the primary
methyl donor for remethylation of homocysteine to
methionine. This means that a low folate status is
associated with increased homocysteine (Hcy) plasma
levels. Genetic deficiency of MTHFR may cause
severe hyperhomocysteinemia and cardiovascular dis-
eases. In 1988, Kang et al.9 described a thermolabile
variant of MTHFR that is associated with decreased
enzyme activity and mildly elevated Hcy plasma
levels. In 1995, Frosst et al.10 identified a 677C→T
mutation in which a cytidine residue at nucleotide
position 677 in the gene coding for the MTHFR
enzyme is replaced by thymidine. Although severe
hyperhomocysteinemia (>150 mmol L−1) causes
atherosclerosis and life-threatening arterial and venous
thromboembolic events in young subjects11, mild Hcy
elevation (>15 mmol L−1) in the adult population
is associated with increased risk of myocardial
infarction, stroke, peripheral arterial disease and
venous thrombosis12–17. The 677C→T mutation
is the most frequent in caucasians; homozygosity
of the thermolabile MTHFR mutant allele occurs
commonly in 5% to 15% of the population, and the
heterozygosity is over 40%18. Moreover, this mutation
shows ethnic differences and it is rare in Afro-
Americans. Homozygous subjects appear to have an
exaggerated hyperhomocysteinemic response to the
depletion of folic acid and the folic acid depletion
may increase the risk for vascular diseases19–21.
Homozygosity for MTHFR 677C→T mutation is
more frequent in epileptic patients compared with
healthy controls (23% vs. 12%) and heterozygosity is
about 52%8. Anticonvulsant drugs, such as phenytoin,
phenobarbitone, primidone and carbamazepine, have
been shown to decrease serum folate levels8. How-
ever, the mechanism by which anticonvulsants induce
folate deficiency is still unknown. Plasma levels of
Hcy and serum folate were inversely correlated in
a study on epileptic patients22. The high frequency
of the MTHFR TT genotype and defective folate
metabolism due to anticonvulsants are independent
risk factors for occlusive vascular diseases and
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could play a role in epileptogenesis. It is not clear
whether impaired Hcy metabolism is related to
epileptogenesis or to alteration of seizure threshold8.
However, Lipton and co-workers23 showed that Hcy
may have excitotoxicity to neurons as an agonist
of the glutamate binding site of the N-methyl-D-
aspartate (NMDA) receptors. In the rat model, it was
demonstrated that an NMDA receptor antagonist is
protective against seizures induced by Hcy24.
In SLE patients the distribution of the MTHFR
genotypes is 50% for the homozygous wild
type, 42% for heterozygous, and 8% for the homozy-
gous mutant7. In our study the thermolabile MTHFR
mutant allele occurred in all of the six SLE patients
with epileptic symptoms: the homozygosity form was
documented in one patient (16.7%), and the heterozy-
gosity forms in five of them (83.3%). Moreover, we
observed a decrease of S protein levels in one case,
high titre positivity (IgG and IgM) of aCL antibodies
in three patients and a low titre positivity (IgG) in one
patient, and LAC positivity in four cases (Table 1).
In the present series, epileptic manifestations were
the SLE onset symptom for three patients (cases
no. 1, 2 and 4), appeared during the active disease
in two cases (no. 5 and 6), and occurred during a
period of clinical remission of SLE in one patient (case
no. 3). Indeed, as reported in the literature, epilepsy
can precede the onset of SLE or occurs at any time
during its course; it can occur during active SLE or
during a quiescent period and may appear as well as
other neurologic events in the same individual7. Two
patients showed simple partial seizures (cases no. 2
and 3), three patients showed complex partial seizures
(cases no. 1, 4 and 6) and one primary generalized
seizures (case no. 5). Three patients displayed a
secondary generalization of partial seizures (cases
no. 1, 2 and 4). We found in all cases fronto-
temporal seizure semeiology, cognitive impairment
and psychopathological disorders.
As previously reported, some anticonvulsant drugs
may determine a low folate status and increased levels
of Hcy, probably by inducing hepatic microsomal
enzymes8. Corticosteroid treatment may also increase
Hcy plasma concentrations directly through its hor-
monal effect7. In our study we have observed the pres-
ence of MTHFR mutation in six SLE patients affected
by epilepsy: the Hcy plasma levels were within the
normal range in all of them, although they had
been taking both anticonvulsants and prednisolone.
It is well known that neurological involvement in
SLE occurs because of multiple mechanisms, such
as thrombotic events and neurotoxic and oxidative
damage. We believe that an impaired Hcy metabolism,
and/or the presence of antiphospholipid antibodies and
LAC, could play a role in epileptogenesis or could be
related to an alteration of the seizure threshold.
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